• Je něco špatně v tomto záznamu ?

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

M. Stork, S. Sevcikova, L. Brozova, I. Spicka, V. Maisnar, J. Minarik, A. Jungova, E. Gregora, R. Velichova, R. Hajek, T. Jelinek, L. Pour,

. 2020 ; 67 (1) : 178-184. [pub] 20191209

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005628

Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005628
003      
CZ-PrNML
005      
20200519140806.0
007      
ta
008      
200511s2020 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2019_190430N383 $2 doi
035    __
$a (PubMed)31829027
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Stork, M $u Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
245    10
$a Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data / $c M. Stork, S. Sevcikova, L. Brozova, I. Spicka, V. Maisnar, J. Minarik, A. Jungova, E. Gregora, R. Velichova, R. Hajek, T. Jelinek, L. Pour,
520    9_
$a Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a lidé $7 D006801
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a recidiva $7 D012008
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sevcikova, S $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Brozova, L $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Spicka, I $u 1st Medical Department, Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
700    1_
$a Maisnar, V $u 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Minarik, J $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Jungova, A $u Hematology and Oncology Department , Charles University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Gregora, E $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Velichova, R $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Hajek, R $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Jelinek, T $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Pour, L $u Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 1 (2020), s. 178-184
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31829027 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200519140802 $b ABA008
999    __
$a ok $b bmc $g 1524486 $s 1095684
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 67 $c 1 $d 178-184 $e 20191209 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace